The increased antioxidant action of HDL is independent of HDL cholesterol plasma levels in triple-negative breast cancer

Imagem de Miniatura
Arquivos
art_CAMPOS_The_increased_antioxidant_action_of_HDL_is_independent_.PDF (872.17 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
CAMPOS, Amarilis de Lima
SAWADA, Maria Isabela Bloise Alves Caldas
IBORRA, Rodrigo Tallada
REIS, Mozania
CARVALHO, Jacira Xavier de
GEBRIM, Luiz Henrique
Citação
FRONTIERS IN ONCOLOGY, v.13, article ID 1111094, 9p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IntroductionThe association between high-density lipoprotein cholesterol (HDLc) with the incidence and progression of breast cancer (BC) is controversial. HDL removes excess cholesterol from cells and acts as an antioxidant and anti-inflammatory. BC is a heterogeneous disease, and its molecular classification is important in the prediction of clinical and therapeutic evolution. Triple-negative breast cancer (TNBC) presents higher malignancy, lower therapeutic response, and survival rate. In the present investigation, the composition and antioxidant activity of isolated HDL was assessed in women with TNBC compared to controls. MethodsTwenty-seven women with a recent diagnosis of TNBC, without prior treatment, and 27 healthy women (control group) paired by age and body mass index (BMI) were included in the study. HDL and low-density lipoprotein (LDL) were isolated from plasma by discontinuous density gradient ultracentrifugation. Plasma lipid profile and HDL composition (total cholesterol, TC; triglycerides, TG; HDLc; phospholipids, PL) were determined by enzymatic colorimetric methods. ApoB and apo A-I were quantified by immunoturbidimetry. The antioxidant activity of HDL was determined by measuring the lag time phase for LDL oxidation and the maximal rate of conjugated dienes formation in LDL incubated with copper sulfate solution. The absorbance (234 nm) was monitored at 37 degrees C, for 4 h, at 3 min intervals. ResultsThe control group was similar to the TNBC concerning menopausal status, concentrations, and ratios of plasma lipids. The composition of the HDL particle in TC, TG, PL, and apo A-I was also similar between the groups. The ability of HDL to retard LDL oxidation was 22% greater in the TNBC group as compared to the control and positively correlated with apoA-I in HDL. Moreover, the antioxidant activity of HDL was greater in the advanced stages of TNBC (stages III and IV) compared to the control group. The maximum rate of formation of conjugated dienes was similar between groups and the clinical stages of the disease. DiscussionThe results highlight the role of HDL as an antioxidant defense in TNBC independently of HDLc plasma levels. The improved antioxidant activity of HDL, reflected by retardation in LDL oxidation, could contribute to limiting oxidative and inflammatory stress in advanced stages of TNBC.
Palavras-chave
breast cancer, triple-negative breast cancer, HDL, LDL oxidation, antioxidant
URI
https://observatorio.fm.usp.br/handle/OPI/52835
Referências
  1. Almansour NM, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.836417
  2. Bobin-Dubigeon C, 2022, J CLIN MED, V11, DOI 10.3390/jcm11051345
  3. Borgquist S, 2016, INT J CANCER, V138, P2648, DOI 10.1002/ijc.30013
  4. Cao WM, 2004, CANCER RES, V64, P1515, DOI 10.1158/0008-5472.CAN-03-0675
  5. Cedo L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060853
  6. Danilo C, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3483
  7. de Gonzalo-Calvo D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1469-5
  8. Eghlimi R, 2020, J PROTEOME RES, V19, P2367, DOI 10.1021/acs.jproteome.0c00038
  9. Fan Y, 2015, INT J BIOL MARKER, V30, pE200, DOI 10.5301/jbm.5000143
  10. FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  11. Furlong CE, 2010, CHEM-BIOL INTERACT, V187, P355, DOI 10.1016/j.cbi.2010.03.033
  12. Ganjali S, 2019, TRENDS ENDOCRIN MET, V30, P12, DOI 10.1016/j.tem.2018.10.004
  13. Georgila K, 2019, CANCERS, V11, DOI 10.3390/cancers11081097
  14. Guan XF, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1075-7
  15. Gutierrez-Pajares JL, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00338
  16. Ha M, 2009, CANCER CAUSE CONTROL, V20, P1055, DOI 10.1007/s10552-009-9301-7
  17. Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48
  18. His M, 2014, EUR J EPIDEMIOL, V29, P119, DOI 10.1007/s10654-014-9884-5
  19. Iborra RT, 2008, SCAND J MED SCI SPOR, V18, P742, DOI 10.1111/j.1600-0838.2007.00748.x
  20. Kim Y, 2009, CANCER EPIDEM BIOMAR, V18, P508, DOI 10.1158/1055-9965.EPI-08-0133
  21. Kucharska-Newton AM, 2008, ANN EPIDEMIOL, V18, P671, DOI 10.1016/j.annepidem.2008.06.006
  22. Li X, 2017, BREAST, V32, P1, DOI 10.1016/j.breast.2016.11.024
  23. Lofterod T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4568-2
  24. LOWRY OH, 1951, J BIOL CHEM, V193, P265
  25. Martin LJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv032
  26. Mazidi M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010170
  27. Mazzuferi G, 2021, LIPIDS HEALTH DIS, V20, DOI 10.1186/s12944-021-01562-1
  28. Medina-Diaz IM, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11040697
  29. Namiri-Kalantari R, 2015, BIOFACTORS, V41, P153, DOI 10.1002/biof.1205
  30. Nowake C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06467-9
  31. Pandrangi SL, 2022, MEMBRANES-BASEL, V12, DOI 10.3390/membranes12050532
  32. Samadi S, 2019, J CELL BIOCHEM, V120, P5756, DOI 10.1002/jcb.27862
  33. Sawada MIBAC., 2022, PREPRINT, DOI [10.21203/rs.3.rs-1663300/v1, DOI 10.21203/RS.3.RS-1663300/V1]
  34. Sung H., 2021, CA-CANCER J CLIN, V71, P209, DOI [10.3322/caac.21660, DOI 10.3322/caac.21660]
  35. Thompson EW, 2022, JACC-BASIC TRANSL SC, V7, P1, DOI 10.1016/j.jacbts.2021.10.010
  36. VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345
  37. Wei YH, 2021, SCI PROGRESS-UK, V104, DOI 10.1177/00368504211028395
  38. Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984
  39. Yuan BY, 2016, TUMOR BIOL, V37, P3581, DOI 10.1007/s13277-015-4141-4

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - ODS/03